HALO - Halozyme Therapeutics, Inc.
| Previous Close | 15.85 |
| Open | 15.96 |
| Bid | 15.00 x 2200 |
| Ask | 17.09 x 1400 |
| Day's Range | 15.96 - 16.38 |
| 52 Week Range | 13.24 - 18.85 |
| Volume | 981,232 |
| Avg. Volume | 872,295 |
| Market Cap | 2.382B |
| Beta (3Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.44 |
- Thomson Reuters StreetEvents
Edited Transcript of HALO earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Halozyme Therapeutics Inc Earnings Call
Motley FoolHalozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript
HALO earnings call for the period ending June 30, 2019.
- Zacks
Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 41.18% and -0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Halozyme Reports Second Quarter 2019 Results
- Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year Period - - ENHANZE® Partner Janssen Submits Regulatory Applications for Subcutaneous Formulation of DARZALEX® in the ...
- Simply Wall St.
Is Halozyme Therapeutics (NASDAQ:HALO) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
- Zacks
Earnings Preview: Halozyme Therapeutics (HALO) Q2 Earnings Expected to Decline
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference
SAN DIEGO , July 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 39th Annual ...
- PR Newswire
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
SAN DIEGO , July 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
- Zacks
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.
- PR Newswire
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
SAN DIEGO, July 19, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) has submitted an extension application to the European Medicines Agency (EMA) for the subcutaneous delivery of DARZALEX® (daratumumab) for patients with multiple myeloma. "We are pleased that Janssen's filing follows quickly after its filing last week of a Biologics License Application (BLA) with the U.S. Food and Drug Administration," said Dr. Helen Torley, President and CEO.
- PR Newswire
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
SAN DIEGO, July 17, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using Halozyme's proprietary ENHANZE® drug delivery technology. "Since the signing of our collaboration with argenx earlier this year, we have made strong progress and I am delighted that the first phase 1 trial has been initiated in such a short amount of time," said Dr. Helen Torley, President and CEO of Halozyme. Initiation of this study triggers a $5 million milestone payment to Halozyme during the current quarter under the global collaboration and license agreement between the two companies.
- PR Newswire
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
SAN DIEGO , July 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator ...
- Simply Wall St.
The Halozyme Therapeutics (NASDAQ:HALO) Share Price Has Gained 99% And Shareholders Are Hoping For More
By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...
- PR Newswire
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
- NIAID to Study Use of ENHANZE® Technology with Broadly Neutralizing Antibodies for Development of New HIV Treatments - SAN DIEGO , June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today ...
- Markit
See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding HALO are favorable, with net inflows of $2.25 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey
Is Halozyme Therapeutics, Inc. (HALO) A Good Stock To Buy?
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
- PR Newswire
Halozyme To Participate In Upcoming Investor Conferences
SAN DIEGO , June 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor ...
- Simply Wall St.
Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Balance Sheet Strong Enough To Weather A Storm?
Stocks with market capitalization between $2B and $10B, such as Halozyme Therapeutics, Inc. (NASDAQ:HALO) with a size...
- PR Newswire
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
SAN DIEGO, May 22, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019. The second target selected for development by argenx is human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases. Halozyme will receive a $10 million milestone payment during the current quarter from argenx for this target nomination and potential future payments of up to $160 million subject to achievement of specified development, regulatory and sales-based milestones.
- Zacks
Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.
- PR Newswire
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America ...
Motley FoolHalozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript
HALO earnings call for the period ending March 31, 2019.
- Zacks
Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
